^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    quavonlimab/pembrolizumab (MK-1308A)

    i
    Other names: MK-1308A, MK-1308/MK-3475
    Associations

    News

    Trials
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    24d
    MK-6482-012 China Extension: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study (clinicaltrials.gov)
    P3, N=249, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan) • quavonlimab/pembrolizumab (MK-1308A)
    1m
    KEYMAKER-U02 Substudy 02D: Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) (clinicaltrials.gov)
    P1/2, N=56, Completed, Merck Sharp & Dohme LLC | N=300 --> 56 | Trial completion date: Apr 2030 --> Oct 2025 | Trial primary completion date: Apr 2030 --> Oct 2025 | Active, not recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • quavonlimab/pembrolizumab (MK-1308A)
    3ms
    KEYMAKER-U02 Substudy 02B: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) (clinicaltrials.gov)
    P1/2, N=315, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Apr 2030 --> Apr 2026 | Trial primary completion date: Apr 2030 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • vibostolimab (MK-7684) • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A)
    4ms
    KEYSTEP-004: Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) (clinicaltrials.gov)
    P2, N=116, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Jul 2025 | Trial primary completion date: Mar 2026 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Lenvima (lenvatinib) • quavonlimab/pembrolizumab (MK-1308A)
    5ms
    KEYMAKER-U02 Substudy 02B: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) (clinicaltrials.gov)
    P1/2, N=315, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • vibostolimab (MK-7684) • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A)
    6ms
    Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) (clinicaltrials.gov)
    P2, N=302, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2027 --> Apr 2026 | Trial primary completion date: Jun 2026 --> May 2025
    Trial completion date • Trial primary completion date • Mismatch repair • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR • RAS wild-type
    |
    Keytruda (pembrolizumab) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • vibostolimab/pembrolizumab (MK-7684A)
    7ms
    KEYMAKER-U03B: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) (clinicaltrials.gov)
    P1/2, N=370, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Sep 2025 --> May 2026 | Trial primary completion date: Sep 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A)
    12ms
    Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) (clinicaltrials.gov)
    P2, N=320, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Nov 2025 --> Jun 2027 | Trial primary completion date: Oct 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • Mismatch repair • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR • RAS wild-type
    |
    Keytruda (pembrolizumab) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • vibostolimab/pembrolizumab (MK-7684A)
    1year
    Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Merck Sharp & Dohme LLC | Active, not recruiting --> Recruiting | N=80 --> 110 | Trial completion date: Nov 2026 --> Nov 2029 | Trial primary completion date: Nov 2026 --> May 2026
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    Lenvima (lenvatinib) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • raludotatug deruxtecan (DS-6000)
    over1year
    Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) (clinicaltrials.gov)
    P2, N=320, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Mismatch repair • Metastases
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • vibostolimab/pembrolizumab (MK-7684A)
    over1year
    MK-6482-012 China Extension: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study (clinicaltrials.gov)
    P3, N=249, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2027 --> Dec 2026 | Trial primary completion date: Jun 2027 --> Dec 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan) • quavonlimab/pembrolizumab (MK-1308A)
    over1year
    Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) (clinicaltrials.gov)
    P1/2, N=400, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan) • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • vibostolimab/pembrolizumab (MK-7684A)